UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $51.10 Million Holdings in Charles River Laboratories International, Inc. $CRL

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 225,314 shares of the medical research company’s stock after acquiring an additional 6,401 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Charles River Laboratories International were worth $51,099,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Los Angeles Capital Management LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter worth $42,000. Sfam LLC purchased a new position in Charles River Laboratories International during the fourth quarter worth about $43,000. Geneos Wealth Management Inc. boosted its stake in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the last quarter. Elyxium Wealth LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth $46,000. Finally, Allworth Financial LP boosted its holdings in shares of Charles River Laboratories International by 61.3% in the 4th quarter. Allworth Financial LP now owns 350 shares of the medical research company’s stock worth $70,000 after buying an additional 133 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 3.3%

Shares of CRL opened at $291.79 on Thursday. The firm’s 50-day moving average price is $251.93 and its 200-day moving average price is $199.91. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $13.93 billion, a price-to-earnings ratio of -60.16, a PEG ratio of 2.77 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $303.30.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter in the previous year, the business posted $3.12 EPS. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. TD Cowen raised their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Morgan Stanley lifted their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Royal Bank Of Canada boosted their price target on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Finally, CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a report on Monday, July 20th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $255.65.

Insider Buying and Selling

In other news, Director James C. Foster sold 33,561 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $9,478,800. This represents a 51.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 165,990 shares of company stock valued at $42,606,388 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.